PURPOSE: Preclinical studies have shown synergy between everolimus, an mTOR inhibitor, radiation, and platinum agents. We conducted a phase IB trial to determine the recommended phase II dose of everolimus with carboplatin and radiation. MATERIALS AND METHODS: Patients with stage II/III esophageal cancer were enrolled. Following 2 cycles of Capecitabine/Oxaliplatin (XELOX), patients with no disease progression, received 50.4 Gy in 28 fractions and concurrent weekly carboplatin (area under the curve=2), with escalating doses of everolimus. A standard 3+3 dose escalation design was used. RESULTS: Nineteen patients were enrolled. Two patients were screen failures and 4 were removed due to poor tolerance to XELOX (n=2) or disease progression (n=2). All treated patients had adenocarcinoma. Median age was 58 (44 to 71 y) and 85% were male patients. One patient at dose level 1 was replaced due to ongoing anxiety. One of 6 patients had a dose-limiting toxicity of bowel ischemia that was fatal. At dose level 2, two of 6 patients had a dose-limiting toxicity (fever with neutropenia and nausea). The recommended phase II dose of everolimus was 2.5 mg QOD. Grade ≥3 toxicities included lymphopenia (11%), nausea (10%), low white blood cell (8.0%) vomiting (5.5%), decreased neutrophils (4.0%). All patients achieved an R0 resection with a pathologic response rate of 40% and a pathologic complete response (ypCR) rate of 23%. The 2-year progression-free survival and overall survival were 50% and 49.6%, respectively. CONCLUSIONS: The recommended phase II dose of everolimus with concurrent weekly carboplatin and radiation is 2.5 mg QOD.
PURPOSE: Preclinical studies have shown synergy between everolimus, an mTOR inhibitor, radiation, and platinum agents. We conducted a phase IB trial to determine the recommended phase II dose of everolimus with carboplatin and radiation. MATERIALS AND METHODS:Patients with stage II/III esophageal cancer were enrolled. Following 2 cycles of Capecitabine/Oxaliplatin (XELOX), patients with no disease progression, received 50.4 Gy in 28 fractions and concurrent weekly carboplatin (area under the curve=2), with escalating doses of everolimus. A standard 3+3 dose escalation design was used. RESULTS: Nineteen patients were enrolled. Two patients were screen failures and 4 were removed due to poor tolerance to XELOX (n=2) or disease progression (n=2). All treated patients had adenocarcinoma. Median age was 58 (44 to 71 y) and 85% were male patients. One patient at dose level 1 was replaced due to ongoing anxiety. One of 6 patients had a dose-limiting toxicity of bowel ischemia that was fatal. At dose level 2, two of 6 patients had a dose-limiting toxicity (fever with neutropenia and nausea). The recommended phase II dose of everolimus was 2.5 mg QOD. Grade ≥3 toxicities included lymphopenia (11%), nausea (10%), low white blood cell (8.0%) vomiting (5.5%), decreased neutrophils (4.0%). All patients achieved an R0 resection with a pathologic response rate of 40% and a pathologic complete response (ypCR) rate of 23%. The 2-year progression-free survival and overall survival were 50% and 49.6%, respectively. CONCLUSIONS: The recommended phase II dose of everolimus with concurrent weekly carboplatin and radiation is 2.5 mg QOD.
Authors: Zev A Wainberg; Heloisa P Soares; Ravi Patel; Brian DiCarlo; David J Park; Andre Liem; He-jing Wang; Lisa Yonemoto; Diego Martinez; Isett Laux; Meghan Brennan; J Randolph Hecht Journal: Cancer Chemother Pharmacol Date: 2015-05-13 Impact factor: 3.333
Authors: E Deutsch; C Le Péchoux; L Faivre; S Rivera; Y Tao; J-P Pignon; M Angokai; R Bahleda; D Deandreis; E Angevin; C Hennequin; B Besse; A Levy; J-C Soria Journal: Ann Oncol Date: 2015-02-20 Impact factor: 32.976
Authors: E Díaz-Rubio; T R J Evans; J Tabemero; J Cassidy; J Sastre; M Eatock; D Bisset; P Regueiro; J Baselga Journal: Ann Oncol Date: 2002-04 Impact factor: 32.976
Authors: Philipp C Manegold; Carmen Paringer; Ulrike Kulka; Klaus Krimmel; Martin E Eichhorn; Ralf Wilkowski; Karl-Walter Jauch; Markus Guba; Christiane J Bruns Journal: Clin Cancer Res Date: 2008-02-01 Impact factor: 12.531
Authors: Seiji Mabuchi; Deborah A Altomare; Mitchell Cheung; Lili Zhang; Poulikos I Poulikakos; Harvey H Hensley; Russell J Schilder; Robert F Ozols; Joseph R Testa Journal: Clin Cancer Res Date: 2007-07-15 Impact factor: 12.531
Authors: Mohan Suntharalingam; Kathryn Winter; David Ilson; Adam P Dicker; Lisa Kachnic; André Konski; A Bapsi Chakravarthy; Christopher J Anker; Harish Thakrar; Naomi Horiba; Ajay Dubey; Joel S Greenberger; Adam Raben; Jeffrey Giguere; Kevin Roof; Gregory Videtic; Jondavid Pollock; Howard Safran; Christopher H Crane Journal: JAMA Oncol Date: 2017-11-01 Impact factor: 31.777
Authors: Charlène J van der Zijden; Ben M Eyck; Ate van der Gaast; Leni van Doorn; Joost J M E Nuyttens; J Jan B van Lanschot; Bas P L Wijnhoven; Bianca Mostert; Sjoerd M Lagarde Journal: Contemp Clin Trials Commun Date: 2022-05-28